Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Dostarlimab-gxly + EOS-448|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Dostarlimab-gxly||Jemperli||TSR-042||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 109||Jemperli (dostarlimab-gxly) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 34313545). Jemperli (dostarlimab-gxly) is FDA approved for use in patients with recurrent or advanced endometrial cancer or solid tumors harboring mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have progressed on prior treatments, and in combination with Paraplatin (carboplatin) and Taxol (paclitaxel), followed by Jemperli (dostarlimab-gxly) monotherapy, in patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high (MSI-H) (FDA.gov).|
|EOS-448||EOS 448|EOS448|EOS884448|GSK4428859A|Belrestotug||TIGIT Antibody 19||EOS-448 is a monoclonal antibody that binds to T cell Immunoreceptor with Ig and ITIM domains (TIGIT) and inhibits ligand interaction, potentially leading to increased antitumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr 3161; Cancer Res 2021;81(13_Suppl):Abstract nr CT118).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05565378||Phase II||Dostarlimab-gxly Dostarlimab-gxly + EOS-448 Pembrolizumab||Phase 2 Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non Small Cell Lung Cancer||Recruiting||USA | ITA | GBR | FRA | ESP | BEL||8|